K-Bio unveils research results on blood cancer treatment at the American Society of Hematology

Domestic bio companies will present their research results one after another at the American Society of Hematology Annual Meeting (ASH 2026) held in New Orleans, USA in December.

According to the bio industry on the 5th, Curocell will present the clinical results of 'Limcato', a chimeric antigen receptor T cell (CAR-T) treatment drug, as a poster at an academic conference.

Curocell plans to disclose long-term follow-up data for up to 44.5 months for patients treated with Limcato.

The long-term response group, which maintained complete remission (the state in which cancer-related signs disappeared) for more than 6 months after administration, had a 3-year survival rate of 81.6% and a progression-free survival rate of 63.0%. This means that more than 8 out of 10 patients who maintain the initial response survive for more than 3 years.

Kim Geon-soo, CEO of Curocell, said, “This long-term tracking data is the result of once again confirming the effectiveness and safety of Limcato,” and added, “We will push for a domestic launch without a hitch within the year.”

GC Cell will present the phase 1a clinical trial results of its cell therapy product 'GCC2005' at this conference.

In the safety evaluation, no dose-limiting toxicity was observed up to the highest dose level, and no serious adverse reactions related to treatment were reported.

In the initial efficacy evaluation, anti-tumor activity was observed, and positive initial treatment responses were confirmed, such as complete remission maintained for a long time in some patients.

Won Seong-yong, CEO of GC Cell, said, “Based on confirmed safety and early clinical results, we will pursue the ongoing phase 1b clinical trial without a hitch, establish the optimal dose, and speed up the process to continue global clinical development.”

RigaChem Bioscience announces that the preclinical test results of 'LCB122A', a CD33 targeting antibody-drug conjugate (ADC) under development, showed superior anticancer efficacy than the approved CD33 ADC (Mylotak).

RigaChem Bio plans to pursue a global phase 1 clinical trial targeting patients with relapsed or refractory acute myeloid leukemia (AML).

In addition, RigaChem Bio announced that it will announce the interim results of the phase 1 clinical trial of 'IKS03', the ADC of its partner Iksuda Therapeutics.

In addition, HLB Innovation [024850] will present at the academic conference the interim results of the phase 1 clinical trial of 'SynKIR-310', a blood cancer CAR-T treatment drug being developed by its U.S. subsidiary Verismo Therapeutics.